Canada markets closed

Curis, Inc. (CRIS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
15.72-0.79 (-4.78%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close16.51
Open16.65
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.72 - 16.65
52 Week Range0.38 - 17.49
Volume12,039
Avg. Volume25,619
Market Cap96.191M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-8.62
Earnings DateAug 01, 2024 - Aug 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.75
  • PR Newswire

    Curis to Present Updated Data from the TakeAim Leukemia Study

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET.

  • Insider Monkey

    Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript

    Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript May 7, 2024 Curis, Inc. misses on earnings expectations. Reported EPS is $-2.0534 EPS, expectations were $-1.94. CRIS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and […]

  • PR Newswire

    Curis Provides First Quarter 2024 Business Update

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.